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ABSTRACT 15 
The hexanucleotide repeat in the first intron of the C9orf72 gene is the most significant 16 
cause of amyotropic lateral sclerosis as well as some forms of fronto-temporal 17 
dementia. The C9orf72 protein has been previously reported to be expressed in post-18 
mortem human brain as well as in late embryonic and some postnatal stages in mice. 19 
Herein, we present a detailed study of the distribution of C9orf72 protein in the 20 
embryonic, postnatal and adult mouse brain,spinal cord as well as during the 21 
differentiation of P19 embryonal carcinoma cells to neurons including motor neurons. 22 
We show that the expression levels of the C9orf72 transcripts in the developing and 23 
adult mouse brain as well as in differentiating neurons, is dynamic. Besides the strong 24 
expression in the cerebellum and motor cortex reported previously, we show for the 25 
first time that C9orf72 is expressed strongly in the olfactory bulb and also in the 26 
hippocampus. Our immunostaining data also reveals a hitherto unreported switch in 27 
the cellular distribution of C9orf72 from a predominantly cytoplasmic to a nucleo-28 
cytoplasmic distribution during corticogenesis. This switch in distribution was also 29 
observed during differentiation of the pluripotent embryonal carcinoma P19 cell line to 30 
mature neurons. Our findings have implications in interpreting the pathophysiology 31 
caused by the repeat expansions in C9orf72 in mouse models. 32 
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INTRODUCTION 38 
Amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD) are two 39 
neurodegenerative diseases that have overlapping genetic causes and pathological 40 
features (Ling et al., 2013).  In ALS, upper and lower motor neurons (MNs) die rapidly 41 
and progressively with fatal consequences. In FTD,  which is the second most 42 
common form of dementia, the frontal and temporal lobes of the brain are affected 43 
(Van Langenhove et al., 2012). At least 15% of patients diagnosed with either disease 44 
have been shown to have symptoms characteristic of the other (Ringholz et al., 2005; 45 
Wheaton et al., 2007). Common cellular pathologies include aberrant RNA processing 46 
and protein homeostasis (Ling et al., 2013). Genetic causes underlying these diseases 47 
have been identified within these pathways, such as mutations in ubiquilin-2, FUS, 48 
TDP-43 and C9orf72 (DeJesus-Hernandez et al., 2011; Deng et al., 2011; Kabashi et 49 
al., 2008; Kwiatkowski et al., 2009; Renton et al., 2011). 50 
Mutations in C9orf72 was first identified by DeJesus-Hernandez et al  and  51 
Renton et al in 2011 in ALS and ALS-FTD patients.). The mutation in C9orf72 takes 52 
the form of a G4C2 hexanucleotide repeat expansion (HRE) in the first intron of the 53 
C9orf72 gene. Typically, up to 20 repeats are found in the normal allele while 54 
pathological alleles carry many additional repeats, ranging from ~30 to thousands. The 55 
HRE has multiple consequences within the cell. The three main pathological 56 
manifestations of the expansion are the appearance of RNA foci, formation of 57 
dipeptide proteins and reduced levels of the C9orf72 protein. The stable G-quadruplex 58 
formed by the HRE DNA and RNA result in RNA foci which have been shown to 59 
sequester factors involved transcription and splicing leading to dysfunction (Fratta et 60 
al., 2012; Lee et al., 2013). Repeat associated non-ATG translation results in the 61 
synthesis of dipeptide repeats (DPR) which have been shown to form intracellular 62 
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inclusions. These aggregates are suggested to be cytotoxic and are found in 63 
degeneration-associated neuronal subtypes (Schludi et al., 2015), as are RNA foci. 64 
Other reports find no evidence for the cytotoxicity of the DPRs (Mackenzie et al., 65 
2015). However, both DPRs and RNA foci are not necessarily co-incidental (Zu et al., 66 
2013) indicating both mechanisms may contribute separately to the aetiology of the 67 
disease. Further evidence for this can be seen in the spinal cord of ALS subjects which 68 
contain RNA foci but rarely DPRs (Cooper-Knock et al., 2015; Gomez-Deza et al., 69 
2015). Reduced C9orf72 expression has been found in ALS-FTD patients by multiple 70 
groups, however, conditional ablation of C9orf72 in mouse does not lead to a 71 
pathological phenotype arguing against haplo-insufficiency as a major contributor to 72 
pathophysiology (Koppers et al., 2015). 73 
FTLD , a form of FTD is best characterised by degeneration of the frontal and 74 
temporal lobes. However, MRI studies have also identified atrophy in the 75 
hippocampus, entorhinal cortex and cerebellum  in FTLD (Hartikainen et al., 2012; 76 
Laakso et al., 2000; Tan et al., 2014). In addition to characteristic abnormalities in the 77 
corticospinal and cerebellar white matter (Bede et al., 2014), C9orf72 ALS-FTD 78 
patients also show increased atrophy in the anterior temporal, parietal and occipital 79 
lobes, as well as the cerebellum, when compared to phenotypes caused by mutations 80 
in other FTD causative genes (Bede et al., 2013; Whitwell et al., 2012).  81 
The C9orf72 protein has been detected in the cortex and cerebellum in human 82 
post mortem brain lysates. Besides these two regions, a few studies have looked at 83 
other regions of the human brain (Gijselinck et al., 2012; Hsiung et al., 2012; Stewart 84 
et al., 2012; Waite et al., 2014; Xiao et al., 2015). Both Gijselinck et al., (Gijselinck et 85 
al., 2012) and Waite et al., (Waite et al., 2014)  have shown decreased levels of 86 
C9orf72 in ALS-FTD brains. Using isoform specific antibodies, Xiao et al., (Xiao et al., 87 
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2015) have shown the strongest expression of the C9orf72 human long isoform  is in 88 
the motor cortex and cerebellum, while the short isoform is detectable in the motor, 89 
frontal and temporal cortices with strongest expression in the cerebellum. Interestingly 90 
they also show the long isoform is present at reduced levels in ALS-FTD brains with 91 
C9orf72 HRE but not in ALS-FTD brains carrying mutations in other ALS causative 92 
genes, and the converse for the short human C9orf72 isoform.  93 
If the mouse is to serve as a model for ALS-FTD, it is important to ascertain 94 
whether the expression domains of the mouse orthologue of C9orf72 are equivalent 95 
to those found in the human brain. In mice with a lacZ knock-in at the endogenous 96 
C9orf72 locus, the mouse orthologue of C9orf72 (3110043O21Rik, referred to as 97 
mC9orf72) was reported to be expressed  throughout the adult mouse brain (Suzuki 98 
et al., 2013). LacZ expression was undetectable in pre-natal stages which is most 99 
likely to be due the low detection sensitivity of the reporter. Atkinson et al., (Atkinson 100 
et al., 2015) studied mC9orf72 expression in the mouse cortex at E18, P1, P14, P28 101 
and P56 by immunohistochemistry and observed changes in distribution during neurite 102 
outgrowth and synaptogenesis throughout the cortex and hippocampus. Although 103 
expression of mC9orf72 has been demonstrated in the mouse brain it remains unclear 104 
whether the protein is present in domains similar to human C9orf72 and regions 105 
affected in ALS-FTD.  106 
We sought to study in detail the distribution C9orf72 in the mouse brain together 107 
with neuronal and brain region specific markers, and whether its distribution was 108 
regulated both temporally and spatially during embryonic and postnatal brain 109 
development as well as during neuronal differentiation of pluripotent stem cells.  110 
Herein, we show that mC9orf72 distribution in the developing mouse brain in 111 
embryonic (E12.5 to E18.5) and post-natal (up to P35) stages is dynamic in location 112 
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and intracellular distribution. We also describe changes in the distribution of mC9orf72 113 
during the development of the brain, with notable changes seen in the olfactory bulb, 114 
cerebral cortex, hippocampus and cerebellum. Using mixed cultures of cortical 115 
neurons and astrocytes from P0 cortices we stained for the expression of C9orf72 and 116 
cortical layer as well as  astrocyte markers and show that C9orf72 is predominantly in 117 
the neuronal cells and virtually undetectable in the astrocytes. Cortical neurons from 118 
all the cortical layers that we identified by staining for layer specific markers expressed 119 
C9orf72.  We detected a distinct switch in the distribution of C9orf72 from a 120 
predominantly cytoplasmic to a nucleo-cytoplasmic distribution during corticogenesis. 121 
This switch in distribution was also observed during differentiation of pluripotent stem 122 
cells to mature neurons.  123 
  124 
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METHODS 125 
Cell Culture and differentiation 126 
Embryonic Carcinoma P19 cells (Passage 8-9) were cultured in P19 growth medium 127 
containing α-MEM (Gibco Life technologies) supplemented with 10% FCS (Biosera) 128 
and 1% NEAA (Gibco Life technologies) at 370C with 5% CO2. When cells reached 129 
confluency of 70%, approximately every 2 days, they were passaged using 0.05% 130 
trypsin/EDTA (Gibco Life technologies). Embryonic bodies (EBs) were made from P19 131 
cells with the following method, cells were trypsinised using 0.05% trypsin/EDTA and 132 
were seeded in 90mm bacteriological dishes at a density of 2.5 x 105/ml were they 133 
spontaneously formed aggregates. The medium used for the EBs was α-MEM 134 
supplemented with 10% KOSR (Gibco Life technologies) and 1% NEAA. In order to 135 
differentiate the EBs into motor neurons we added 0.5μM Retinoic Acid (Sigma) after 136 
24 hours and after 48 hours they were plated onto matrigel (BD) coated coverslips.  137 
For coating the coverslips we added 200μl of matrigel per coverslip and after 2 hours 138 
at room temperature matrigel was aspirated and the EBs were added. The EBs were 139 
seeded using differentiation medium containing α-MEM, 1% NEAA, 1% KOSR and 140 
0.5μM Retinoic Acid in order to promote differentiation of the EC cells. The 141 
differentiation medium was changed every other day for 6 days and on the 6th day the 142 
it was changed to neurobasal media (Gibco Life technologies), 1x B27 (Life 143 
Technologies), 1% KOSR and 1% glutamax (Life technologies). We continued 144 
changing the medium every 2 days in order to sustain the neuronal culture.    145 
 146 
Western Blot 147 
CD1 mouse brains (P10) were dissected into cerebral cortex and cerebellum, minced 148 
and then snap frozen in liquid nitrogen. Tissue from two mice were thawed with the 149 
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addition of 2% SDS in 60 mM Tris-Cl pH 6.8, pooled and homogenised by Dounce 150 
homogeniser. Lysates were sheared through 21G and 30G needles (BD) then 151 
centrifuged at 13k in a benchtop microfuge. Supernatants were stored at -70ºC. 152 
Protein concentration was determined by BCA microplate assay following 153 
manufacturer's instructions (Pierce). Each sample  (10μg of protein) was mixed with 154 
loading buffer (to final concentrations of 2% SDS, 10% glycerol, 50mM DTT in 60 mM 155 
Tris-Cl pH 6.8), boiled for five minutes and proteins resolved on a 10% polyacrylamide 156 
gel. Proteins were transferred to 0.45µm PVDF at 50V for 90min in transfer buffer 157 
(25mM Tris, 192mM glycine, pH 8.3, 20% methanol).   158 
Blots were blocked in 5% Marvel in PBS for an hour then incubated overnight 159 
in primary antibody (1:1000) diluted in 5% Marvel in PBS at 4⁰C. After four 5min 160 
washes in PBS with 0.1% Tween20 (PBSTw) the blots were incubated with 161 
appropriate Horseradish perxoxidase conjugated secondary antibody (1:10000, 162 
Abcam) diluted in 5% Marvel in PBS. After further 4x5min washes in PBSTw, blots 163 
were incubated with ECL reagent and exposed to film (Amersham hyperfilm). Blots 164 
were imaged on a Fusion SL (Vilber Lourmat) using the associated Fusion-Capt 165 
software. 166 
 167 
qRT-PCR 168 
P19 were lysed in Trizol (Invitrogen) for RNA at indicated time points throughout two 169 
independent differentiation time courses on matrigel in the presence of RA. Tissue 170 
was dissected from CD1 embryos to isolate heads at E12.5, whole brains at E13.5, 171 
E14.5 and E16.5, fore and mid/hind brain at E18.5. Brains was also dissected from 172 
postnatal mice at P5, P10 and P15 and split into cerebrum and cerebellum. Tissue 173 
was snap frozen in trizol and pooled from four individuals from the same litter. Tissue 174 
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in trizol was thawed and disrupted by Dounce homogeniser and RNA prepared 175 
following standard trizol method. RNA was DNased and reverse transcribed using 176 
OligodT primers. qPCR was performed using primers specific to transcripts 1, 2 and 7 177 
and normalised to Actb. Reactions were carried out in a BioRad iQ5 cycler. Dynamic 178 
well factors were collected for 2min 30sec, then forty cycles at 60°C and 95°C for 20s 179 
each followed by a melt curve. Expression levels were determined relative to Actb from 180 
baseline subtracted curves and corrected using primer efficiencies determined 181 
previously from serial dilutions of PCR product. See Table 1 for primer sequences  182 
 183 
Immunohistochemistry 184 
For isolating embryonic stages, pregnant dams were killed by cervical dislocation prior 185 
to dissection. E12.5 and E14.5 embryos were fixed whole. E16.5 embryos were 186 
decapitated prior to fixation. Brains were dissected from E18.5 through post-natal 187 
stages and bisected prior to fixation. Dissected embryos and brains were fixed 188 
overnight in cold 4% PFA, washed twice for 1h with PBS then cryo-protected in 20% 189 
sucrose before embedding in OCT. Frozen blocks were sectioned by Leica cryostat 190 
and air dried for 1h before storage at -20⁰C. 191 
Frozen sections were incubated in PBS twice to remove OCT prior to antigen 192 
retrieval in boiling 10mM Sodium Citrate Buffer, pH 6.0 with 0.05% Tween 20 for 193 
20min. Sections were allowed to cool for 20min, washed twice with PBS and blocked 194 
with 0.1% gelatin in PBS supplemented with 0.5% Triton X-100 and 1% FBS for 1 hour 195 
at room temperature. 196 
Cells on coverslips were washed with PBS and fixed with 4% PFA for 15min. 197 
After two PBS washes cells were dehydrated with serial ethanol washes. Prior to 198 
immunostaining cells were rehydrated, washed with PBS and blocked as for frozen 199 
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sections.Both cells on coverslips and sections were incubated with appropriate 200 
primary antibody at 40C overnight.  The sections and fixed cells were then washed 201 
four times with 0.1% Triton X-100 in PBS and then incubated for 1 hour with the 202 
appropriate secondary antibody together with  4′,6-diamidino-2-phenylindole (DAPI) 203 
(Invitrogen) to stain cell nuclei. See Table 2 for list antibodies used.  Stained sections 204 
and cells on coverslips  were mounted using Mowiol. Imaging was done with a Leica 205 
DMRB5500 epifluorescent microscope. Images were captured and deconvoluted 206 
where required using LAS AF (Leica) and figures composed in Photoshop CS3 207 
(Adobe). Brain anatomy was identified using the Allan Brain Atlas (http://mouse.brain-208 
map.org/). 209 
 210 
RESULTS 211 
Antibody characterisation 212 
Several commercially antibodies are available for researchers seeking to detect 213 
C9orf72 protein. Since several reports comment about their general unsuitability 214 
(Waite et al., 2014; Xiao et al., 2015), we proceeded to characterise the specificity of 215 
two popular C9orf72 antibodies both by western blot using purified recombinant 216 
human C9orf72 protein and also compared them by immunostaining adjacent sections 217 
of adult mouse brain.  218 
The mouse C9orf72 ortholog (3110043O21Rik) encodes three transcripts (1, 2 219 
& 7) producing different protein isoforms, unlike the human C9orf72 which only 220 
produces two (1 & 3) transcripts. Transcript 1 of both mouse and human code for a  221 
481aa protein which have 98% homology at the amino acid level. Mouse transcript 7 222 
encodes only the first 420aa of transcript 1 (Supplementary Material, Fig. S1A). The 223 
second protein coding transcript is substantially different from the first, but also differs 224 
11 
 
dramatically between the two species. Human C9orf72 transcript 2 contains only the 225 
first 222aa of transcript 1 while mouse C9orf72 transcript 2 encodes only the last 226 
317aa of the homologous mouse transcript 1.  227 
 We found that the ProteinTech and SantaCruz antibodies detect both the 228 
481aa and 222aa human C9orf72 isoforms. The ProteinTech epitope however, is 229 
present only in the 481aa and 420aa isoform (transcript 1 &7) of mouse C9orf72 while 230 
the SantaCruz antibody detected all three mouse isoforms (Supplementary Material, 231 
Fig. S1A). 232 
In Western blots both antibodies recognized the pure recombinant human 233 
C9orf72 long isoform  (kind gift from S Iyer and R Acharya , University of Bath). The 234 
SantaCruz C9orf72 antibody produces a more intense signal as compared to the 235 
ProteinTech antibody when used at the same concentration at similar exposure times 236 
in western blots (Supplementary Material, Fig. S1B, ii and iv compared to i and iii). 237 
Additional weak bands seen with the SantaCruz are absent in the blots probed with 238 
the ProteinTech antibody. These additional bands could represent degraded C9orf72 239 
protein at lower masses and multimers at higher (Supplementary Material, Fig. S1B, 240 
II and IV) as we have used C9orf72 protein which has been stored frozen after 241 
purification for our western blot analysis. Such additional bands are frequently seen 242 
upon storage of the purified C9orf72 protein (S Iyer and K Achraya, personal 243 
communication- see lines 363-368 for confirmation). 244 
Comparison between adjacent sections of adult mouse brain immunostained 245 
using both antibodies however, showed very little observable difference 246 
(Representative areas are shown in Supplementary Material, Fig. S2;  A: cerebellum, 247 
B: hind brain and C: cortex). Since in Western blots the Santa Cruz antibody gave 248 
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stronger signal, all our immunostaining as well as further Western blot studies were 249 
carried out using the Santa Cruz C9orf72 antibody. 250 
 251 
C9orf72 isoform expression in the cerebral cortex and cerebellum 252 
Protein extracts from postnatal cerebellum and cortex were  analysed for expression 253 
using  the SantaCruz anti-C9orf72 antibody. The dominant isoform in the brain 254 
appears to be that derived from transcript 1 (481aa, 54kDa) while the isoforms 255 
encoded by transcript 7 (420aa, 47kDa) and transcript 2 (222aa, 36kDa) in both the 256 
cortex and cerebellum (Fig. S1C) were significantly lower. The cerebellum showed 257 
higher levels of C9orf72 isoform 1 when compared to the cortex. 258 
Crude lysates of bacteria expressing recombinant C9orf72 isoform 1, loaded 259 
on the PAGE gel directly without purification identified a single band corresponding to 260 
C9orf72 upon immunoblotting (FigS1C). We did not observe any additional non-261 
specific bands or cross-reactivity with any bacterial proteins in these samples. This 262 
suggests that the additional bands seen with the frozen pure recombinant C9orf72 are 263 
degradation or aggregation products  rather than non-specific bands.  264 
 265 
C9orf72 expression in the developing mouse cerebral cortex  266 
Cortical neurogenesis occurs in the last eight days of gestation in the developing 267 
mouse. The neural progenitors found in the ventricular zone at E12.5 progressively 268 
mature, divide and migrate radially outwards from the cerebral ventricle. By E16.5 this 269 
has resulted in the formation of the distinct sub-ventricular zone, sub-plate and cortical 270 
plate proper. As cortical neurons are born they migrate outwards through the pre-271 
existing cortical plate neurons resulting in an inside out pattern of early-born deep 272 
layers and late-born superficial layers. Concomitantly the sizes of the ventricular and 273 
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sub-ventricular progenitor pools progressively diminish by E18.5 (Dehay and 274 
Kennedy, 2007).    We investigated the pattern of expression of C9orf72 in the 275 
developing mouse cortex from E12.5 though to E18.5.  At early embryonic stages 276 
(E12.5-16.5) we studied the expression of C9orf72 in combination with nestin, the 277 
neural progenitor marker and with the 160kd neurofilament marker. At later embryonic 278 
stages (E16.5-18.5) we studied the co-localisation of C9orf72 with well characterised 279 
markers for each cortical layer. 280 
In the E12.5 developing mouse cerebral cortex (Fig. 1A-D) expression is seen 281 
in regions adjacent to the ventricles both in the ventral and dorsal pallium (Fig. 1A). 282 
C9orf72 expression is seen in radially organized cells that co-express the neuronal 283 
progenitor marker nestin. This is seen specifically at the most medial zones in coronal 284 
sections both dorsal (Fig. 1B) and ventral (Fig. 1C), but is strongest at the dorsal side. 285 
C9orf72 is also detectable in tangentially orientated cells at the superficial surface of 286 
the dorsal pallium (Fig. 1A-B, dotted lines). C9orf72 staining appears to be specific to 287 
neural tissue, as observed at the interface between the strongly stained pre-optic area 288 
and adjacent non-neural tissue (Fig. 1D). Staining appears most intense in developing 289 
forebrain structures, but is does not appear in the sub-pallium or pre-thalamic regions.  290 
The expression of C9orf72 no longer appears concentrated at the ventricular 291 
side of the dorsal pallium at E14.5 but staining more strongly at the superficial surface 292 
of both dorsal pallium (Fig. 1E) and olfactory bulb (Fig. 1F). This pattern of staining is 293 
not observed in the more anterior medial pallium or midbrain (Fig. 1G). Stronger 294 
expression is seen within the superficial stratum of the habenula and the pre-thalamic 295 
structures in areas of reduced cell density directly adjacent to the convolution 296 
separating it from the pallium (Fig. 1H, closed arrows). C9orf72 expression at E14.5 297 
is observed in the superficial zones where the hypothalamus and hindbrain abut (Fig. 298 
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1I, open and closed arrows). Expression is also in the axonal tracts which are 299 
neurofilament positive in the medulla (Fig. 1J, dotted lines) and entering the spinal 300 
cord (Fig. 1K, dotted lines). Neurofilament positive spinal ganglia can also be seen co 301 
expressing C9orf72 (Fig. 1L).  302 
As development proceeds to E16.5, (Fig. 2A), increased expression is no 303 
longer seen around the ventricles, but remains around the tangentially orientated cells 304 
at the pial surface similar to that observed at E14.5. A second zone of increased 305 
expression is present below the cortical plate mid-pallium in the intermediate zone 306 
between the ventricular zone and the cortical plate. This second zone does not overlap 307 
with markers such as Tbr2 in the subventricular zone (SVZ) or Nurr1 in the subplate 308 
(SP). This pattern of staining is not seen in the subiculum, sub-pallium, thalamus or 309 
developing hippocampus.  310 
C9orf72 expression extends through the entire rostro-caudal axis of the pallium 311 
at E18.5 (Fig. 2B).  Expression of late cortical markers such as SatB2 and Ctip2 312 
indicates specification of the upper layers of the cortex in addition to the lower layers 313 
present at E16.5 as shown by the staining for Tbr1. Increased expression of C9orf72 314 
persists in both the intermediate zone and superficial marginal zone of C9orf72. The 315 
expression domains of cortical layer markers confirms that the internal band of 316 
C9orf72 is not part of the cortical plate as it is below the deep layer marker Tbr1 and 317 
is not in the Tbr2 positive SVZ. At this stage increased C9orf72 expression can also 318 
be seen in the superficial region of the midbrain tectum in similar to expression in the 319 
cortical marginal zone.  320 
The intermediate zone of the cortex dramatically decreases in size at P5 and 321 
P10 accompanied by the loss of C9orf72 expression. A gradient of C9orf72 expression 322 
can be seen extending from the marginal zone inwards particularly at early postnatal 323 
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stages (P5 and P10 data not shown) than during embryonic. At P35 (Fig. 2C), the 324 
cortex layering is complete. C9orf72 expression is detected throughout the adult cortex 325 
but is strongest in layer I with a gradual decrease in intensity through to the base of 326 
layer II/II. Further bands of increased C9orf72 expression can be found throughout 327 
layer IV and VI. C9orf72 also appears to have transitioned from being predominantly 328 
cytoplasmic to a more even nucleo-cytoplasmic distribution. 329 
In summary, we find C9orf72 expression throughout the developing cortex, 330 
strongest closer to the ventricle and superficially at E12.5 and E14.5, the intermediate 331 
and superficial marginal zones at E16.5 and E18.5, and then superficially in layers I, 332 
IV and VI in P35 mice. While predominantly cytoplasmic during embryonic stages, 333 
C9orf72 takes on a nucleocytoplasmic distribution post-natally (Table 3). 334 
 335 
C9orf72 expression in cortical neuronal cultures 336 
We also studied the expression of C9orf72 in the cortical neurons and astrocytes 337 
isolated from P0 cortex and co-expression with transcription factor markers for cortical 338 
layers as well as the astrocyte marker GFAP. The primary cortical neurons in culture 339 
stained positive for neurofilament and the synaptic vesicle marker SV2. All the cortical 340 
neurons showed robust C9orf72 expression in neurofilament positive axons while 341 
GFAP+ astrocytes express barely detectable levels in comparison (Fig. 3A, arrows). 342 
We observed no differences in expression or localisation of C9orf72 in cortical neurons 343 
from the different cortical layers as seen by co-staining for  calbindin, SatB2 or Ctip2 344 
(Fig. 3B). 345 
 346 
C9orf72 expression in the developing cerebellum 347 
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The anlage of the cerebellum emerges at at E11.5, however, much of the development 348 
-ie expansion and organisation occurs postnatally until P15. By E18.5, granule cells 349 
precursor cells have migrated tangentially from the rhombic lip to form the external 350 
granule layer (EGL). The Purkinje cells (PC) are born and migrate radially from the 351 
ventricular zone to form the Purkinje cell layer (PCL). As the development of the 352 
cerebellum progresses, granule cells from the ECL descend radially to below the PCL 353 
to form the internal granule cell layer (IGL). By P15 the thickness of the EGL has 354 
substantially reduced, along with the loss of proliferative precursor cells while the IGL 355 
has increased in size. The thickness of the molecular layer between the PCL and EGL 356 
also increases and contains the extensive PC dendritic arborisation and granule cell 357 
parallel fibres or climbing fibres. The expansion of the cerebellum also results in its 358 
foliation and characteristic lobes (Martinez et al., 2013). 359 
Expression of C9orf72 can be seen between the developing external granule 360 
layer (EGL) of the cerebellum at E18.5 and the internal neurofilament positive areas 361 
(Fig. 4A). This band of C9orf72 expression is expanded at P5 and overlaps with the 362 
calbindin positive Purkinje cells in the molecular layer (ML) between the EGL and 363 
internal granule layer (IGL, more defined at this stage), but  staining remains stronger 364 
on the interior edge of the EGL. Both the IGL and ML thicken by P10 when Purkinje 365 
cells have taken on their characteristic positioning on the superficial side of the IGL 366 
(Fig. 4A, pc). This pattern is consistent throughout the lobes and is maintained in the 367 
fully developed cerebellum at P35. The C9orf72 staining is strongest in around the 368 
cells directly adjacent to proliferating PCNA positive EGL granule cells (Fig. 4B). This 369 
persists up to P10 and although by P35 the proliferation and migration in the EGL has 370 
ceased the expression of C9orf72 remains strongest at the most superficial part of the 371 
molecular layer.  372 
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C9orf72 staining does not associate with the tangential GFAP positive glial 373 
fibres extending through the ML at any stage, or with the calbindin positive Purkinje 374 
cell dendrites at E18.5 to P10. At P35 it does appear to be strongest towards the ends 375 
of Purkinje dendrites and does appear to partially overlap with the most superficial 376 
synapses stained by SV2 from E18.5 to P35. Additionally it does not appear 377 
associated with Tbr2 positive granule cell parallel fibres or proliferating EGL which is 378 
strongly positive for PCNA (Fig. 4B).  379 
Closer inspection of the cerebellar molecular layer at P35 showed no overlap 380 
or association between C9orf72 and GFAP positive glial fibres (Fig. 5A). C9orf72 can 381 
however be seen in the cell body of the Purkinje cells (Fig. 5A, arrows) and also 382 
clustering along the length of calbindin positive Purkinje cell dendrites, both proximal 383 
to the cell body and at distal tips. As one would expect from this, no co-localisation is 384 
seen with the post-synaptic marker PSD95, but overlap can be seen between C9orf72 385 
and the synaptic vesicle marker SV2 (Fig. 5B).  386 
To summarise, cerebellar C9orf72 expression is strongest in the regions 387 
underlying the EGL at E18.5. Expression at P5 and P10 overlaps with the PCL and 388 
ML which is adjacent to the EGL. This distribution pattern is maintained through to P35 389 
when very strong C9orf72 expression is seen in the soma and nuclei of PCs as well 390 
as the pre-synaptic terminals in the ML (Table 3). 391 
 392 
C9orf72 expression in the developing olfactory bulb 393 
The olfactory bulb (OB) can first be identified at E12.5 as a protrusion of the rostral 394 
telencephalon. After neurogenesis between E11-13, mitral and tufted cells (M/T cells) 395 
migrate radially into the OB then orientate tangentially prior to dendritic arborisation to 396 
form the external plexiform layer (EPL) between E14 and E16. From E17 onwards 397 
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theses dendrites begin to associate with proto-glomerular structures. Olfactory 398 
glomeruli found in the superficial adult olfactory bulb where sensory neuron axons from 399 
the olfactory epithelium form synapses. Considerable remodelling and pruning of the 400 
M/T cell dendrites occurs post-natally alongside further glomerulogenesis (Treloar et 401 
al., 2010). 402 
The olfactory bulb showed distinct and high levels of C9orf72 expression. At 403 
E16.5 and E18.5, strong expression of C9orf72 is seen in the superficial stratum of the 404 
olfactory bulb compared to the deeper layers (Fig. 6A). By P5 the olfactory bulb has 405 
delineated into distinct regions and strong expression is seen in the olfactory glomeruli, 406 
while individual C9orf72 expressing cells can be identified in the external and internal 407 
plexiform areas (Fig. 6Bii and iii). Staining in the olfactory glomeruli at the superficial 408 
edge of the olfactory bulb increases between P5 and P35 (Fig. 6Bi, glm). C9orf72 409 
staining in the olfactory glomeruli at P35 does not overlap with the presynaptic marker 410 
PSD95 (Fig. 6C, inset).  C9orf72 expression in the external plexiform area is spread 411 
throughout the cells at P5, predominantly at the internal edge of the mitral cell layer 412 
(mcl) and in the molecular layer (ml) (Fig. 6Bii). By P10, the diffuse cytoplasmic 413 
staining has transitioned to a much more defined nucleo-cytoplasmic staining as is 414 
seen in the developing cortex. Strong nucleo-cytoplasmic staining is found in the 415 
internal plexiform area from P5 through to P35 and continues to remain at the same 416 
intensity as the olfactory bulb expands (Fig. 6Biii). See Table 3 for summary of 417 
expression pattern. 418 
 419 
C9orf72 expression in the hippocampus 420 
The hippocampus forms from the dorso-medial telencephalon. The CA fields form 421 
sequentially from the outside in; first the CA3 field is defined at the dentate pole at 422 
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E14.5, then CA1 at the subicular pole from E15.5 then finally between them CA2 takes 423 
on its identity post-natally. The dentate gyrus granule cell layer becomes visible by 424 
E18.5 with stratification of the different cell-types finalising by P1-2. We studied 425 
C9orf72 expression in the P35 adult hippocampus (Khalaf-Nazzal and Francis, 2013). 426 
C9orf72 is not detectable in the nuclei of cells in the granular layer of the dentate 427 
gyrus or the CA fields (Fig. 7A, dg and CA1-3). Strong cytoplasmic expression is seen 428 
extending from the hilus through to the CA3 stratum radiatum (Fig. 7Bi-iv). In the CA3 429 
stratum radiatum, C9orf72 can be seen distributed radially from the granular layer 430 
indicating association with the CA3 neuron dendrites (Fig. 7Biv). This distribution 431 
extends further round to CA2 (Fig. 7Bv) but is not present in CA1 (Fig. 7Bvi) or in the 432 
subiculum. C9orf72 staining also appears to be stronger in the efferent side of CA2 in 433 
the stratum oriens adjacent to the granular layer (Fig. 7Bv). This can also be seen to 434 
a lesser degree in CA1 (Fig. 7Bvi). See Table 3 for summary of expression pattern. 435 
 436 
Expression of C9orf72 in the developing spinal cord 437 
The anterior-posterior patterning of the neural tube leads to the specification of the 438 
pro- mes- and rhomb-encephalon (the early structures which form the fore- mid- and 439 
hind-brain) and the spinal cord. In addition, dorso-ventral patterning occurs between 440 
E9.5-11 in response to BMP/Shh signalling resulting in progenitor domains that will 441 
generate ventral motorneurons, dorsal sensory neurons and interneurons (Lu et al., 442 
2015). Migration and differentiation of the neural crest derived sensory neurons to the 443 
dorsal root ganglia occurs from E9.5 with migration reduced by E11 after which 444 
subtype specification continues to occur (Marmigère and Ernfors, 2007).  445 
We analysed the expression of C9orf72 expression in the spinal cord and dorsal 446 
root ganglia (DRG) in mid-thoracic sections of mouse embryos. We stained for 447 
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neurofilament to identify axons and Islet1/2 to identify post-mitotic motor neurons and 448 
Islet1+ dorsal root ganglion neurons  (Sun et al., 2008). 449 
Expression of C9orf72 is seen throughout the spinal cord but is most intense in 450 
the transverse fibres of the corticospinal and spinothalamic tracts in the lateral and 451 
ventral funiculus at E12.5 (Fig. 8B). C9orf72 expression is similar to the surrounding 452 
tissue where Islet1/2+ motor neurons are found in the ventral horn (Fig. 9A) or in the 453 
more lateral pools (Fig. 9B) at E12.5. Increased expression of C9orf72 is observed in 454 
Islet1+ motor neurons at E14.5 and E16.5 (Fig. 9A). Strong C9orf72 expression can 455 
also be seen in Islet1+ neuronal cell bodies in the dorsal root ganglia at E12.5 with 456 
marked increases in staining intensity at E14.5 continuing until  E16.5 (Fig. 9B). 457 
The intense C9orf72 staining found in the funiculus co-stains with neurofilament 458 
in the descending tracts, particularly at the outermost edge of the spinal cord. At E12.5 459 
staining appears strongest at the ventral funiculus (Fig. S3A) while it appears evenly 460 
distributed between lateral and ventral tracts at E14.5 and E16.5 (Fig. S3B and 8B,C). 461 
Additionally at E14.5 and E16.5 stronger C9orf72 staining can be found in the dorsal 462 
corticospinal tracts (Fig. 8B,C, arrows). See Table 3 for a summary of the expression 463 
pattern. 464 
 465 
C9orf72 expression during in vitro neuronal differentiation from stem cells 466 
In order to better observe the changes in distribution and expression of C9orf72 during 467 
cell differentiation, we monitored the expression of C9orf72 during in vitro 468 
differentiation of P19 embryonal carcinoma cell line to mature motor neurons.  469 
Undifferentiated P19 grow in nests and C9orf72 is seen uniformly in all cells of 470 
the colony (Fig. 10A). C9orf72  expression is predominantly and strongly cytoplasmic 471 
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in a granular punctate manner in the undifferentiated P19 cells, (Fig. 10Ai). After eight 472 
days of differentiation to neurons, C9orf72 is present in both the nucleus and 473 
cytoplasm in the soma in a highly speckled pattern, and can very clearly be seen 474 
concentrated at the membranes in neurite extensions (Fig. 10Aii and iii). To identify 475 
when this transition in cellular distribution occurs, we looked at intervening time points 476 
and co-immunostained with markers characteristic of the different stages of 477 
differentiation. Early speckled cytoplasmic staining is found on day two and day four 478 
(Fig. 10B-D, white arrows). A small proportion of cells on day four have begun to show 479 
the later speckled C9orf72 distributed more evenly between nucleus and cytoplasm 480 
(Fig. 10B-D, black arrows). By day eight the majority of cells exhibit this nucleo-481 
cytoplasmic staining in the cell body.  482 
Expression of nestin, an early neuronal precursor marker, starts off uniformly 483 
expressed in all cells on day two (Fig. 10B). By day seven it has increased in intensity, 484 
processes have begun to extend and C9orf72 can be seen in these processes. By day 485 
eight, nestin positive processes have been replaced by neurofilament and nucleo-486 
cytoplasmic staining is seen in the nestin negative cells with neuronal morphology. 487 
Underlying these cells, nestin positive but C9orf72 negative epithelial-like cells can be 488 
seen (Fig. 10B, asterisk), mirroring the pattern of C9orf72 seen with neurons and glia 489 
in the brain.  490 
Expression of neurofilament indicating mature neurons and the frequency of 491 
C9orf72 positive neurites, increases between day six and eight and cell bodies 492 
associated with neurofilament positive neurites have nucleo-cytoplasmic C9orf72 493 
staining rather than strongly cytoplasmic alone (Fig. 10C, asterisks). A later marker of 494 
neuronal maturity, the synaptic vesicle marker SV2, is weakly expressed on day four 495 
but can be seen expressed robustly on day eight, distributed throughout neurites and 496 
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neuronal cell bodies (Fig. 10D). Again SV2 is present in neuronal cells which stain 497 
positive for the speckled nucleo-cytoplasmic C9orf72 distribution. The C9orf72 498 
staining in the neurites appear stronger where SV2 is being expressed (Fig. 10D, 499 
asterisk). Around 20% of the neurons generated by day eight are motor neurons and 500 
stain positive for the transcription factors Islet1/2 (Fig. 10E). P19 derived motor 501 
neurons display the same intracellular distribution of C9orf72 as other P19 derived 502 
neurons (Fig. 10F).  503 
Quantitation of C9orf72 transcript specific expression during development and 504 
in vitro differentiation 505 
We also quantified the levels of the different mouse C9orf72 transcripts during 506 
embryonic and postnatal mouse developments as well as in adult brain to support the 507 
immunohistochemistry data.  C9orf72 transcript 1 shows a steady increase in levels 508 
throughout the embryonic stages to E18.5 when a clear change in expression levels 509 
can be seen with lower levels in mid/hind brain (Fig. 11A). During postnatal stages 510 
expression of C9orf72 transcript 1 appears to reach steady levels between P5 and 511 
P15 in the cerebrum while a rapid increase in expression levels can be seen in the 512 
cerebellum from P5 onwards. C90rf72 transcript 2 also appears to steadily increase 513 
during development. During postnatal stages, C9orf72 transcript 2 appears to increase 514 
in expression in both the cerebrum and cerebellum concurrently to similar levels by 515 
P15. C9orf72 transcript 2 is initially present at levels below that of C9orf72 transcript 516 
1 and 7 but reaches similar levels at least in the cerebrum by P15. The expression 517 
levels of C9orf72 transcript 7 expression at all stages appears to be between that of 518 
transcript 1 and 2. Its expression follows a pattern more similar to C9orf72 transcript 519 
2 with a concurrent increase in expression in both cerebrum and cerebellar tissue from 520 
P5.  521 
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Analysis of expression of the three C9orf72 transcripts during neuronal 522 
differentiation of pluripotent P19 cells showed a steady increase in expression over 523 
the time course of the differentiation similar to the steady increase in levels seen by 524 
immunostaining (Fig. 11B). There is no sudden peak during the time course as seen 525 
during the developmental series from post-natal stages.  By day sixteen, expression 526 
of C9orf72 transcript 1 and 2 peaked at levels but below that of post-natal mouse 527 
brains. C9orf72 transcript 2 levels appear higher than in embryonic brains. C9orf72 528 
transcript 7 appears to peak midway through the differentiation and maintain a steady 529 
level until day 16 where it appears to have dropped dramatically.  530 
 531 
DISCUSSION 532 
 533 
C9orf72 is linked to neurodegenerative diseases, and the hexanucleotide repeat 534 
expansions in the first intron of this gene have been shown to cause neuronal cell 535 
death but very little is known about the  distribution , cellular function or normal role for 536 
the C9orf72 gene product in the adult brain or during  neuronal differentiation. We 537 
have observed substantial region specific differences in expression domains in the 538 
developing and adult brain, such as increased levels in particular cortical layers. We, 539 
like Atkinson et al., (Atkinson et al., 2015), show that C9orf72 protein is detected 540 
throughout the mouse brain in a punctate speckled manner.  In addition we have 541 
analysed the distribution of C9orf72 in early embryonic stages. We also show hitherto 542 
unreported notable expression in the olfactory bulb, hippocampus and cerebellum in 543 
addition to the cortex which is traditionally associated with FTD.  We show in addition, 544 
that novel distinct changes occur both in the domains of expression of C9orf72 as well 545 
as in the intracellular localisation. This is not an artefact of tissue processing as we 546 
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also demonstrate this switch in distribution using an in vitro model of neuronal 547 
differentiation. 548 
In contrast to the lacZ knock-in mouse used by Suzuki et al., (Suzuki et al., 549 
2013) where lacZ appeared more frequently in the projection neurons of Layer V and 550 
Layer II/III, we found that in the adult cortex increased C9orf72 staining in layers I, IV 551 
and VI. This may be due to the lacZ expression highlighting the cell body of the 552 
C9orf72 positive neuron while the immunostaining we observed highlights synapses 553 
clustered around dendritic processes. This is particularly apparent in the staining seen 554 
in layer I, a molecular layer consisting of large numbers of apical dendrites from 555 
pyramidal cells in lower layers. During development C9orf72 can be seen as a distinct 556 
layer in the intermediate zone where neuronal precursors are migrating from the 557 
proliferating progenitors in the ventricular zone through to the nascent cortical plate.  558 
The involvement of the cerebellum in FTD is unclear and patients do not show 559 
classic signs of cerebellar defects such as ataxia. Despite this, atrophy in the 560 
cerebellum has been identified in C9orf72 ALS-FTD patients (Bocchetta et al., 2016; 561 
Hornberger, 2012; Tan et al., 2014) and p62 positive inclusion bodies have been 562 
identified in the cerebellum as well as the cortex in FTD (King et al., 2009). These 563 
inclusions are present in patients with C9orf72 HREs and those found in the cortex, 564 
hippocampus and cerebellum have been shown to contain dipeptide repeat proteins 565 
(Davidson et al., 2014; Mann et al., 2013; May et al., 2014). However in contrast to the 566 
strong localisation of  C9orf72 seen by us in the molecular layer of the cerebellum, 567 
DPR inclusions are typically found in the cell bodies on the internal granule layer which 568 
are the source of the projections into the molecular layer.  569 
In the hippocampus, the strongest expression of C9orf72 is within the granule 570 
cells of the dentate gyrus and pyramidal cells of CA2/3 where DPR deposits are found 571 
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in human patients  but not in the CA1. (Davidson et al., 2014; Mann et al., 2013; May 572 
et al., 2014). Therefore expression of the DPR from the HRE may be linked to overall 573 
expression levels of the C9orf72 gene or expression of a particular transcript. In 574 
agreement with our observation that transcript 1 is dramatically upregulated during 575 
post-natal development of the cerebellum and increased levels of C9orf72 protein in 576 
the expanding cerebellar molecular layer, Atkinson et al., (Atkinson et al., 2015) show 577 
the transcript 1 55kDa isoform is highly enriched in synaptosome preparations.  578 
Olfactory defects and impaired sense of smell have been identified in some 579 
cases of FTD although this is more commonly associated with Alzheimer’s and 580 
Parkinson’s disease (AD and PD) (Heyanka et al., 2014; Luzzi et al., 2007; Orasji et 581 
al., 2016; Pardini et al., 2009). The olfactory glomeruli is a structure dense with 582 
synapses and is the first level of synaptic processing in the olfactory system (Hamilton 583 
et al., 2005). As with the molecular layers of the cortex and cerebellum, C9orf72 584 
staining is particularly intense in this region. C9orf72 can be also be seen in the cells 585 
of the internal and external plexiform areas.  586 
Suzuki et al (2013) did not observe C9orf72 expression in astrocytes and 587 
microglia. In mixed cultures of cortical neurons and astrocytes we found that C9orf72 588 
expression was virtually undetectable in astrocytes but strongly expressed in the 589 
neurons. Similarly in the spinal cord we observed expression  in spinal motor neurons 590 
as well as the DRGs. 591 
C9orf72 is predicted to be a DENN-domain protein (differentially expressed in 592 
normal and neoplastic cells) (Levine et al., 2013; Zhang et al., 2012). This family of 593 
proteins are Rab guanine nucleotide exchange factors (RabGEFs) which together with 594 
Rab family GTPases are involved in membrane and vesicular trafficking (Marat et al., 595 
2011; Stenmark, 2009). In the mouse brain and in P19 derived neurons, we observed 596 
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that C9orf72 expression and localisation was closely linked to the synaptic vesicle 597 
marker SV2 and dense pre-synaptic areas. Consistent with this, the densest C9orf72 598 
staining and SV2 overlap was seen in the molecular layer of the adult mouse 599 
cerebellum where granule cell axons form synapses with Purkinje dendrites.   600 
Xiao et al., (Xiao et al., 2015) using isoform specific antibody, described the 601 
intracellular localisation of the long C9orf72 isoform in Purkinje cells as diffuse in the 602 
cytoplasm with distinct speckles within the cell body. As of now there is no description 603 
of the distribution of the long human C9orf72 isoform for other areas of the human 604 
brain. Interestingly, Xiao et al., (Xiao et al., 2015) show that the short human isoform 605 
has a very distinct association with the nuclear membrane in Purkinje cells. While the 606 
human short isoform is the first 222aa of the human long isoform, the mouse short 607 
isoform comprises the last 317aa of transcript 1. Because of this it is not possible to 608 
predict what the role of the shorter mouse isoform may be in comparison to human 609 
without further characterisation.  610 
We also show a distinct switch in intracellular localisation of C9orf72 from a 611 
predominantly cytoplasmic distribution predominantly in early developmental stages, 612 
to a marked increase in nuclear C9orf72 in addition to the cytoplasmic expression as 613 
neurons mature in the brain. We see this switch distinctly in the developing cortex and 614 
the external plexiform area of the olfactory bulb, and it is recapitulated in vitro during 615 
P19 differentiation to mature neurons. A few previous studies have shown C9orf72 616 
distribution in mature neurons, however, we are the first to demonstrate the early 617 
cytoplasmic distribution followed by a switch to nuclear and cytoplasmic distribution in 618 
mature neurons. Nuclear import of C9orf72 is not well characterised and the protein is 619 
not predicted to contain an NLS however Xiao et al., (Xiao et al., 2015) have shown 620 
association of both human C9orf72 isoforms with importin-β1, lamin B and Ran-621 
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GTPase by immunostaining and immunoprecipitation. What triggers this shift in 622 
distribution is unclear. Whether or not this difference in C9orf72 distribution has an 623 
effect on the role of the protein during neurogenesis is unknown. The Alzheimer’s 624 
disease associated proteins presenilin and ApoE have been shown to have a role in 625 
adult hippocampal neurogenesis (Chevallier et al., 2005; Kiyota et al., 2015; Mu and 626 
Gage, 2011) as does the FTD-associated progranulin (Arrant et al., 2015).  627 
In order to better characterise the sub-cellular localisation in vitro and in vivo 628 
epitope tag knock-in approach will be informative. In this approach normal C9orf72 629 
expression would be unaffected, potentially yielding clearer results over the 630 
heterozygous knock-out required in LacZ gene-trap methods (Suzuki et al., 2013).  631 
Our study is the first to provide a detailed characterisation of the expression 632 
domains and localisation of C9orf72 protein within the tissues of the mouse brain, from 633 
early embryonic stages through to mature adult. We also confirm others descriptions 634 
of intracellular distribution in mature cells and show a novel C9orf72 distribution within 635 
neuronal precursors. The correlation between C9orf72 expression domains and FTD-636 
affected areas highlights that understanding the role of C9orf72 during normal 637 
development and cellular function will yield insight into FTD-ALS pathology. 638 
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TABLES 875 
Table 1 – qRT-PCR Primers 
Transcript 
(Accession) 
Primer 
Name 
Sequence 5’-3’ 
Product 
(bp) 
Transcript 1 
(3110043O21Rik-
001) 
mC9T1 F AGCGGCGAGTGGCTATTG 
162 
mC9T1 R CAAAGGTAGCCGCCAACAAG 
Transcript 2 
(3110043O21Rik-
002) 
mC9T2 F GGCGAGTGGGAAAGACAAGA 
104 
mC9T2 R ACTTCCCCAGTAAGCATGGG 
Transcript 7 
(3110043O21Rik-
007) 
mC9T7 F AGTGAAAGCCTTCCTGGATCA 
190 
mC9T7 R GGGAACGAACAGCAACTGTC 
ActB 
(NM_001101.3) 
mActB-F ACCATGGATGATGATATCGC 
281 
mActB-R TCATTGTAGAAGGTGTGGTG 
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Table 2 – Antibodies used in this study 
Target Dilution  Supplier Cat# 
C9orf72 1:500 ProteinTech 22637-1-AP 
C9orf72 1:500 SantaCruz SC138763 
Nestin 1:50 DSHB Rat 401 
Neurofilament 1:5 DSHB 2H3 
Pax6 1:500 Covance PRB-278P 
Tbr2 1:500 Abcam Ab23345 
Nurr1 1:100 R&D AF2156 
Tbr1 1:500 Abcam Ab31940 
Satb2 1:100 Abcam Ab51502 
Ctip2 1:500 Abcam Ab18465 
Cux1 1:50 SantaCruz SC13024 
GFAP 1:500 Sigma A2052 
Calbindin 1:4000 Swant 300 
SV2 1:5 DSHB SV2 
PCNA 1:2000 Cell Signalling 2586 
PSD95 1:200 Neuro-mAb K28/43 
Islet1/2 1:5 DSHB 40.2D6 
Alexa Fluor 488, Goat anti-
mouse 
1:1000 Invitrogen A-11001 
35 
 
Alexa Fluor 488, Goat anti-
rabbit 
1:1000 Invitrogen A-11035 
Alexa Fluor 568, Goat anti-
mouse 
1:1000 Invitrogen A-11004 
Alexa Fluor 594, Goat anti-
rabbit 
1:1000 Invitrogen A-11012 
Alexa Fluor 488, Goat anti-rat 1:1000 Invitrogen A-11006 
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FIGURES AND LEGENDS 891 
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 894 
Figure 1 – C9orf72 is present in the early embryonic brain and spinal cord 895 
37 
 
Immunostaining for C9orf72 and nestin in E12.5 embryos (A-D) in sagittal (A) and 896 
coronal (B-D) orientations. Strong C9orf72 staining can be seen in the dorsal pallium 897 
of the telecephalon (A), in the superficial layer of the rostral pallium (B) as well as in 898 
regions adjacent to the caudal secondary proencephalic ventricle (csp) in a radial 899 
arrangement spanning outwards (dotted lines). A similar pattern is seen in the caudal 900 
subpallium (C) adjacent to the rostral secondary proencephalic ventricle (rsp). C9orf72 901 
is strongest in neuronal tissues, as shown by expression in the pre-optic area (D, po) 902 
adjacent to non-neuronal tissue. Immunostaining for C9orf72 and nestin (E-I) or 903 
neurofilament (J-L) in E14.5 brain. Expression seen is strongest in the superficial 904 
layers of the caudal rostral pallium (E) and pre-olfactory pallium (F). This pattern of 905 
expression is not seen in the caudal midbrain tectum (G). Strong staining again is 906 
found in the superficial layer of the hippocampal allocortex (H, ha, open arrows) and 907 
spread in deeper layers of the adjacent thalamic tissue (th, closed arrows). Strong 908 
staining is also seen in the superficial layer of the rostral hypothalamus (rh) and 909 
prepontine hindbrain (pph) (I). C9orf72 can be found aligned with neurofilament 910 
positive tracts in the medulla (J) and spinal cord (K). C9orf72 and neurofilament are 911 
found together in the spinal ganglia (L). Scale bars 100µm.   912 
 913 
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Figure 2 – Layer specific C9orf72 distribution changes in the developing and 920 
adult cortex 921 
Immunostaining for C9orf72, neurofilament and layer specific markers in adjacent 922 
sections of the brain. At E16.5 (A) the cortex is divided into the Pax6+ ventricular zone 923 
(vz), Tbr2+ subventricular zone (svz), intermediate zone (iz), Nurr1+ subplate (SP), 924 
Tbr1+ layer VI/cortical plate (CP) and finally the marginal zone (mz) at the pial surface. 925 
C9orf72 expression appears throughout but is strongest in the marginal and 926 
intermediate zones. At E18.5 (B), further layers have formed in the cortical plate 927 
(layers II/II-VI, marked by SatB2 and Ctip2). Strong expression continues in the 928 
marginal zone  and in a narrower region of the intermediate zone. By P35 all the layers 929 
of the cortex have formed (C) an the intermediate zone is absent. C9orf72 staining 930 
remains strongest in layer I at the pial surface and is also seen strongly in upper 931 
portions of layer II, throughout layer IV and the middle of layer VI. C9orf72 has also 932 
switched from a mainly cytoplasmic distribution at embryonic stages to a more uniform 933 
distribution with staining seen throughout the cytoplasm and nucleus. Scale bars 934 
100µm.   935 
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Figure 3 – C9orf72 is highly expressed in primary cortical neurons in 943 
comparison to glia 944 
Strong expression of C9orf72 is seen in the cell body and neurites of neurofilament 945 
positive cultured primary cortical neurons isolated at P0 (A). C9orf72 expression in 946 
GFAP positive glial cells is largely undetectable (A, arrows). C9orf72 expression is 947 
found consistently in all cortical neuron subtypes identified (B). Scale bars 50µm.   948 
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Figure 4 – C9orf72 is strongly expressed in the molecular layer of the developing 953 
and adult cerebellum 954 
Expression of C9orf72 in the developing cerebellum from E18.5 to P35 (A). C9orf72 955 
staining is not seen in the neurofilament positive internal structures at any stage, but 956 
is found strongly at the inner edge of the developing external granule layer (EGL) at 957 
E18.5 which then goes onto to expand as the molecular layer (ML) expands, between 958 
the EGL and calbindin (CalB) positive Purkinje cell bodies (pc) adjacent to the forming 959 
inner granule layer (IGL).  Scale bars 500µm.   960 
Throughout cerebellar development (B) C9orf72 expression in the molecular layer is 961 
not associated with Bergmann glia (GFAP) or proliferating granule cells (PCNA) but 962 
does associate with Purkinje dendrites (CalB) and synapses (SV2). C9orf72 appear 963 
strongest at the most superficial part of the molecular layer. Scale bars 50µm.   964 
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Figure 5 – C9orf72 in the adult cerebellar molecular layer is pre-synaptic 970 
The molecular layer in the adult cerebellum (p35) shows no association of C9orf72 971 
with Bergman glia fibres (GFAP), but clustered staining can be found directly adjacent 972 
to calbindin positive Purkinje dendrites (A, inset, dotted outline). C9orf72 expression 973 
can also be seen within the Purkinje cell body (arrow). C9orf72 shows no overlap with 974 
the post-synaptic marker PSD95 but co-localises with the synaptic vesicle marker SV2 975 
(B). Scale bars 20µm.   976 
 977 
 978 
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Figure 6 – C9orf72 is strongly expressed in the olfactory bulb 987 
Between E16.5 and E18.5 expression is seen in the superficial layer of the olfactory 988 
bulb (A) scale bars 200µm.  989 
In post-natal mice from P5 onwards, C9orf72 expression is found in in three distinct 990 
olfactory layers (B); the glomerular (i), internal (ii) and external plexiform areas (iii). 991 
Between P5 and P10 the distribution of C9orf72 in the mitral cell layer of the external 992 
plexiform area (mcl) changes from a predominantly cytoplasmic to one with increased 993 
nuclear staining. C9orf72 staining in the olfactory glomeruli (glm) becomes more 994 
distinct as the size and frequency of glomeruli increases with age. C9orf72 in the 995 
glomeruli (C) is strongly co-incident with PSD95 but without overlap similar to the 996 
cerebellum . Scale bars 250µm. 997 
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Figure 7 – C9orf72 in the hippocampus is found in areas associated with the 1000 
mossy fibre tracts 1001 
An intense band of C9orf72 can be seen extending from the hilus (hi) of the dentate 1002 
gyrus (dg) to the stratum radiatum (sr) of the CA3 field and part of CA2 (A). It does not 1003 
appear as tracts between the granule layer (gl) and CA3sr (B, i-iii), but can be seen 1004 
organised radially from the CA3 stratum pyramidale (sp) (B, iv). Further C9orf72 1005 
staining can be seen at the efferent stratum oriens (so) adjacent to the CA2 sp (B, v). 1006 
C9orf72 staining is not as distinct in the CA1 or the subiculum (s) (B, vi). Allen Brain 1007 
Atlas expression data (C) shows strong expression in the dg but not CA3 granule 1008 
layers. Scale bars 100µm. 1009 
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Figure 8 - Overview of C9orf72 expression in the developing spinal cord 1011 
Transverse sections of mid-thoracic spinal cord from the indicated embryonic stages. 1012 
Comparison of adjacent sections immunostained with either Isl1/2 or Neurofilament 1013 
(NF) and C9orf72, counterstained with DAPI at E12.5 (A), E14.5 (B) and E16.5 (C). 1014 
Motor pools highlighted by dashed boxes. Ventral spinal cord (i) shown in detail in 1015 
figures 8A and S4A. Dorsal root ganglion shown in detail in figures 8B and S4B. Arrows 1016 
indicate dorsal corticospinal tracts. Scale bars 100µm. 1017 
Transverse sections of mid-thoracic region of indicated embryonic stages, stained with 1018 
anti-C9orf72 and and anti-Islet1/2 (Isl1/2) antibodies , counterstained with DAPI.  1019 
C9orf72 expression in the ventral spinal cord is strongest in the transverse tracts of 1020 
the lateral (lf) and ventral funiculus (vf) at E12.5. Increased expression can be seen in 1021 
the motor neuron pool in the ventral root (vr) from E14.5 to E16.5 (A). C9orf72 1022 
expression is also found in the dorsal root ganglia with expression increasing from 1023 
E12.5 to E16.5. Scale bars 100µm. 1024 
  1025 
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Figure 9 – Neurons differentiated from pluripotent P19 cell line including motor 1030 
neurons show a nucleo-cytoplasmic change in C9orf72 distribution during 1031 
differentiation  1032 
Undifferentiated P19 cells show a predominantly cytoplasmic distribution of C9orf72 1033 
but after differentiation to neurons, distribution is more nuclear and C9orf72 can also 1034 
be seen on the cell membranes in neurites (A). The early cytoplasmic distribution of 1035 
C9orf72 is found in nestin positive neuronal precursors seen on days two and four 1036 
while nestin negative mature neurons display increased nuclear C9orf72 (B). C9orf72 1037 
is found weakly within nestin positive processes (B, asterisk). Neurofilament 1038 
expression follows nestin and as expected, increased nuclear C9orf72 is seen in 1039 
mature neurofilament positive neurons (C). C9orf72 expression also seems to be 1040 
found at higher levels in neurofilament positive neurites (C, asterisk). The presence of 1041 
synaptic vesicle marker SV2 indicates mature axons (D), the strongest C9orf72 1042 
staining is found in SV2 positive neurites (D, asterisk). The motor neuron (MN) marker 1043 
Islet1/2 expression can be seen on day eight (E) and C9orf72 expression in MNs  is 1044 
similar to other neurons present in the culture (F). Scale bars 25µm. 1045 
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Figure 10 – C9orf72 expression levels increase throughout development and 1050 
differentiation in the CNS 1051 
Expression levels of mC9ORF79 transcripts relative to Actb determined by qRT-PCR. 1052 
(A) C9orf72 expression in a developmental series of mouse brains; E12.5 head; E14.5 1053 
and E16.5 brains; E18.5 fore and mid/hind brain; P5, 10 and 15 cerebrum and 1054 
cerebellum. RNA from four siblings pooled in duplicate. Levels of all three transcripts 1055 
increase over development, particularly transcript 1 in the cerebellum. (B) A time 1056 
course of C9orf72 expression in P19 embryonal carcinoma cells differentiated on 1057 
matrigel as described in Methods at the indicated time points. As with transcripts in 1058 
brain tissue, all three C9orf72 transcripts appear to steadily rise during differentiation.  1059 
RNA from two independent experiments and all reactions performed in triplicate.  1060 
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 1062 
Supplementary Figure 1 – Comparison of two C9orf72 antibodies by Western 1063 
blot 1064 
ClustalO alignment of mouse and human C9orf72 protein isoforms showing antibody 1065 
epitopes (A). Western blot for purified recombinant human C9orf72 using either 1066 
ProteinTech (PT) or SantaCruz (SC) primary antibody showing a strong band at 55kDa 1067 
for His-tagged C9orf72 isoform 1 (B). Western blot of P10 mouse cortex and 1068 
cerebellum using SantaCruz primary antibody shows isoform 1 is the predominant 1069 
form (C). Each lane represents tissue pooled from two mice. Gapdh used as loading 1070 
control. Unpurified bacterial lysate of recombinant human his-tagged C9orf72 isoform 1071 
1 used as positive control (rC9).  1072 
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Supplementary Figure 2 – Comparison of two C9orf72 antibodies by 1075 
immunostaining on brain sections 1076 
Comparison of adjacent sections of mouse brain immunostained with either 1077 
ProteinTech or SantaCruz anti C9orf72 antibody and counterstained with DAPI in the 1078 
cerebellum (C), hind brain (D) and cortex (E).  1079 
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Supplementary Figure 3 – C9orf72 expression in the spinal cord is associated 1084 
strongly with neurofilament  1085 
Transverse sections of mid-thoracic spinal cord from the indicated embryonic stages. 1086 
Stained with C9orf72 and neurofilament (NF), counterstained with DAPI. C9orf72 1087 
expression in the ventral spinal cord is strongest in the transverse tracts of the lateral 1088 
(lf) and ventral funiculus (vf) at E12.5 (A). C9orf72 expression is also found with 1089 
associated neurofilament in the dorsal root ganglia with expression increasing from 1090 
E12.5 to E16.5. Scale bars 100µm. 1091 
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